Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics director Amit Munshi reported a forfeiture of previously issued shares. On February 21, 2026, 19,089 shares of common stock were returned to the company after a milestone related to the February 21, 2025 CorHepta Pharmaceuticals acquisition was not achieved. Munshi received no cash or other consideration for this disposition to the issuer.
Following the forfeiture, he holds 38,176 shares of common stock directly and 365,000 shares indirectly through the Amit Munshi Revocable Trust.
Inhibikase Therapeutics, Inc. attracted a significant institutional holder, with ADAR1-affiliated entities reporting beneficial ownership of 9.9% of its common stock. ADAR1 Capital Management, ADAR1 Capital Management GP and manager Daniel Schneeberger report shared voting and dispositive power over between 12.5 million and 12.7 million shares, including milestone warrant shares.
The holdings span limited partnerships, a Spearhead Insurance vehicle and separately managed accounts, with additional milestone warrants contractually limited by a 9.99% beneficial ownership cap. Ownership percentages are based on 120,899,650 Inhibikase common shares outstanding as of November 24, 2025.
Inhibikase Therapeutics, Inc. received an amended Schedule 13G/A showing that Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Harwin and Tomas Kiselak collectively report beneficial ownership of 12,461,101 shares of Common Stock, representing 9.9% of the class.
The position consists of 8,625,000 shares held by Fund II and the current right to acquire 3,836,101 additional shares through pre-funded warrants, limited by a 9.99% “Beneficial Ownership Limitation.” The 9.9% stake is calculated against 124,461,101 shares of Common Stock outstanding as of the filing date.
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class. This total includes shares underlying pre-funded and common warrants held by Perceptive Life Sciences Master Fund, Ltd., subject to a 9.99% ownership cap on warrant exercise.
The ownership percentage is based on 120,899,650 shares outstanding as of a recent prospectus supplement, and reflects shared voting and dispositive power among Perceptive Advisors, Joseph Edelman, and the Master Fund. The group certifies the holdings are not for the purpose of changing or influencing control of Inhibikase.
Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack report their beneficial ownership of Inhibikase Therapeutics common stock on an amended Schedule 13G. As of December 31, 2025, they may be deemed to beneficially own 7,037,916 shares, or 5.68% of the outstanding common stock.
This total includes 3,108,624 shares that could be acquired within sixty days through warrant exercises. The reporting persons state they share voting and dispositive power over these shares and certify the holdings are in the ordinary course of business, not for the purpose of changing or influencing control.
Sands Capital Life Sciences Pulse Fund II, L.P. and related entities report a 10.8% beneficial stake in Inhibikase Therapeutics, Inc. They collectively hold 13,018,965 shares of common stock, based on 120,899,650 shares outstanding as of November 20, 2025, as referenced in the issuer's prospectus supplement.
The filing explains that this ownership is attributed to Sands Capital Life Sciences Pulse Fund II, its investment manager Sands Capital Alternatives, LLC, and Frank M. Sands, who has ultimate voting and investment power. It also describes additional Series A-1 and Series B-1 warrants held by the fund that are not counted as beneficially owned because they are not exercisable within 60 days and are subject to a 19.99% ownership cap after exercise.
Inhibikase Therapeutics, Inc. reported a new stock option grant to its Chief Executive Officer and director, Mark T. Iwicki. On January 5, 2026, he was awarded a stock option covering 4,982,706 shares of common stock at an exercise price of $2.01 per share.
The option is described as a right to buy common stock and had no purchase price at grant. It becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and each vesting installment depends on his continued employment through that vesting date. The option relates to 4,982,706 underlying common shares and is scheduled to expire on January 5, 2036, if not exercised earlier.
Inhibikase Therapeutics reported that President & Head of R&D Cabell Christopher received a grant of stock options on January 5, 2026. The award covers 900,117 stock options, each with an exercise price of $2.01 per share, giving the right to buy common stock. According to the disclosure, the options vest in 36 equal monthly installments starting January 5, 2026, and vesting is conditioned on Christopher’s continued employment through each vesting date. Following this grant, Christopher beneficially holds 900,117 derivative securities directly.
Inhibikase Therapeutics reported an insider equity award for its Chief Financial Officer, David McIntyre. He received a stock option grant covering 986,319 shares of common stock at an exercise price of $2.01 per share on January 5, 2026. The option was granted at a cost of $0 on the grant date, so no shares were bought or sold in this transaction.
The option vests and becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and is scheduled to expire on January 5, 2036. Following this grant, McIntyre beneficially owns derivative securities representing 986,319 option rights held directly.
Sands Capital Life Sciences Pulse Fund II, L.P. filed a Form 4 reporting a purchase of 2,068,965 shares of Inhibikase Therapeutics, Inc. (IKT) common stock in an underwritten public offering on 11/21/2025 at $1.45 per share. Following this transaction, the fund reports holding 13,018,965 shares directly.
The filing is made jointly by related entities, including Sands Capital Alternatives, LLC and affiliates, with the reporting persons identified as a director and 10% owner of IKT. Footnotes explain that additional Series A-1 and Series B-1 warrants to purchase 5,475,000 and 10,068,120 shares of common stock, respectively, are not included in the reported beneficial ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership cap.